“In the bladder cancer field, there's been a renewed shift on looking at environmental exposures,” says Kyle A. Richards, MD, FACS.
In this video, Kyle A. Richards, MD, FACS, highlights potential future work building off of the study, “The impact of Agent Orange exposure on non-muscle invasive bladder cancer outcomes”. Richards is an associate professor of urology at the University of Wisconsin-Madison.
Video Transcript:
We really need to look at environmental exposures, not necessarily Agent Orange. Although we would like to look at Agent Orange exposure in patients with more advanced bladder cancer to also test this hypothesis to see if they had similar or worse outcomes. In the bladder cancer field, there's been a renewed shift on looking at environmental exposures, because although one of the most common risk factors for bladder cancer is smoking, rates of smoking have declined over the past few decades, but rates of bladder cancer have not. So, that tells us that there must be other environmental risk factors out there. I think there's been a renewed interest in that area of work.
My group here at the University of Wisconsin have collaborated with some veterinarians in the vet med school to try to identify other environmental causes. There are certain breeds of dogs, Scottish terriers, for example, that have very high rates of bladder cancer. So, we're working to try to figure out some of the other environmental risk factors to see if we can mitigate those environmental exposures and maybe clean up the environment a little bit more.
This transcription has been edited for clarity.
Coding Q&A: Billing for female total urethrectomy with complete cystectomy
January 5th 2024"When we think about a typical procedure for performing a radical cystectomy for cancer with an ileal conduit, that would typically involve lymph node dissection, and therefore CPT 51595 would be best chosen to report that combined procedure," write Jonathan Rubenstein, MD, and Mark Painter.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.